Announcements Trials
Browse Landscape

Phase

Phase 3 6Phase 2 6Phase EARLY_PHASE1 2Phase NA 1Phase 4 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Neuroendocrine Tumors 43Carcinoma, Neuroendocrine 22Small Cell Lung Carcinoma 13Carcinoma, Non-Small-Cell Lung 12Neoplasms 11Sarcoma 10Lung Neoplasms 9Thyroid Carcinoma, Anaplastic 7Thyroid Cancer, Papillary 7Stomach Neoplasms 7Pheochromocytoma 7Paraganglioma 7Head and Neck Neoplasms 7Gastro-enteropancreatic neuroendocrine tumor 7Carcinoid Tumor 7Thyroid Neoplasms 6Neoplasm Metastasis 6Colorectal Neoplasms 6Ovarian Neoplasms 5Breast Neoplasms 5Uterine Cervical Neoplasms 4Thyroid Diseases 4Thoracic Neoplasms 4Respiratory Tract Neoplasms 4Respiratory Tract Diseases 4Prostatic Neoplasms 4Neuroblastoma 4Neoplasms by Site 4Multiple Endocrine Neoplasia Type 1 4Lung Diseases 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Pituitary ACTH Hypersecretion × Endocrine × Clear all
NCT05804669 2025-04-10

A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome

Crinetics Pharmaceuticals Inc.

Phase 1/2 Recruiting
18 enrolled
Endocrine

ACTH Syndrome, Ectopic, Cushing Syndrome, Pituitary ACTH Hypersecretion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡